Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson's Disease and Its Inherent Risk for Melanoma.
Parkinson’s disease
dermatofluoroscopy
melanin
neuromelanin
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
15 06 2019
15 06 2019
Historique:
received:
30
04
2019
revised:
07
06
2019
accepted:
13
06
2019
entrez:
19
6
2019
pubmed:
19
6
2019
medline:
19
6
2019
Statut:
epublish
Résumé
Parkinson's disease is associated with an increased risk of melanoma (and vice versa). Several hypotheses underline this link, such as pathways affecting both melanin and neuromelanin. For the first time, the fluorescence of melanin and neuromelanin is selectively accessible using a new method of nonlinear spectroscopy, based on a stepwise two-photon excitation. Cutaneous pigmentation and postmortem neuromelanin of Parkinson patients were characterized by fluorescence spectra and compared with controls. Spectral differences could not be documented, implying that there is neither a Parkinson fingerprint in cutaneous melanin spectra nor a melanin-associated fingerprint indicating an increased melanoma risk. Our measurements suggest that Parkinson's disease occurs without a configuration change of neuromelanin. However, Parkinson patients displayed the same dermatofluorescence spectroscopic fingerprint of a local malignant transformation as controls. This is the first comparative retrospective fluorescence analysis of cutaneous melanin and postmortem neuromelanin based on nonlinear spectroscopy in patients with Parkinson's disease and controls, and this method is a very suitable diagnostic tool for melanoma screening and early detection in Parkinson patients. Our results suggest a non-pigmentary pathway as the main link between Parkinson's disease and melanoma, and they do not rule out the melanocortin-1-receptor gene as an additional bridge between both diseases.
Identifiants
pubmed: 31208049
pii: cells8060592
doi: 10.3390/cells8060592
pmc: PMC6627191
pii:
doi:
Substances chimiques
Melanins
0
neuromelanin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Neurochem Res. 2016 Dec;41(12):3356-3363
pubmed: 27662849
Neurosci Lett. 1998 Sep 11;253(3):198-200
pubmed: 9792245
Ann Neurol. 2017 Mar;81(3):395-406
pubmed: 28019657
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Arch Dermatol. 1988 Jun;124(6):869-71
pubmed: 3377516
Biomolecules. 2015 Jun 05;5(2):1122-42
pubmed: 26057626
Nature. 2012 Nov 15;491(7424):449-53
pubmed: 23123854
Neurol Genet. 2016 Apr 13;2(3):e70
pubmed: 27123489
Pigment Cell Melanoma Res. 2011 Jun;24(3):438-45
pubmed: 21457482
Ann Neurol. 2016 Feb;79(2):306-16
pubmed: 26606657
Int J Cancer. 2011 May 15;128(10):2251-60
pubmed: 21207412
J Natl Cancer Inst. 2015 Dec 17;108(3):
pubmed: 26683220
Neurology. 2009 Oct 20;73(16):1286-91
pubmed: 19841380
J Mol Neurosci. 2014 Dec;54(4):820-5
pubmed: 25284244
Photochem Photobiol. 2009 Jan-Feb;85(1):387-90
pubmed: 19067944
Int J Cancer. 2008 Jun 15;122(12):2753-60
pubmed: 18366057
Brain. 2005 Nov;128(Pt 11):2654-64
pubmed: 16000336
Mov Disord. 2015 Nov;30(13):1848-52
pubmed: 26395561
Br J Dermatol. 2018 Aug;179(2):478-485
pubmed: 29569229
Arch Neurol. 2010 Mar;67(3):347-52
pubmed: 20212233
Ann Clin Transl Neurol. 2017 Feb 24;4(3):212-216
pubmed: 28275654
Acta Neuropathol. 2017 Apr;133(4):535-545
pubmed: 28180961
J Neural Transm Suppl. 2006;(70):119-23
pubmed: 17017518
PLoS One. 2010 May 05;5(5):e10481
pubmed: 20463956
Mayo Clin Proc. 2017 Jul;92(7):1070-1079
pubmed: 28688464
Dermatol Surg. 2016 Feb;42(2):141-6
pubmed: 26771684
PLoS One. 2014 Oct 21;9(10):e110804
pubmed: 25333933
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5956-61
pubmed: 12719539